-
動態
6月10日9:30，仁醫醫療三人團隊前往哥廷根大學醫療中心，拜訪病理科主任、哥廷根癌症中心副主任、國際病理學學會德國分會主席Ströbel 教授，並就中德在精準病理診斷領域的合作進行了深入交流。Ströbel教授是德國病理學界的重要人物，曾參與主筆世界衛生組織（WHO）2004、2015與2021年版腫瘤分類標準中有關肺、胸膜、胸腺和心髒腫瘤的病理學和遺傳學章節。作為2025年德國病理學年會主席，他將於6月12日至14日在萊比錫主持這一年度學術盛會。哥廷根大學創立於1737年，是德國最古老、學xue術shu氛fen圍wei最zui濃nong厚hou的de大da學xue之zhi一yi，其qi附fu屬shu醫yi療liao中zhong心xin是shi下xia薩sa克ke森sen州zhou南nan部bu唯wei一yi被bei認ren證zheng的de最zui高gao等deng級ji醫yi療liao服fu務wu提ti供gong者zhe，在zai德de國guo醫yi學xue體ti係xi中zhong占zhan據ju核he心xin地di位wei。其qi病bing理li科ke每mei年nian處chu理li約yue4.5萬個病例，製作評估約20萬份組織學樣本，診斷流程已全麵實現電子化。科研方麵設有5個由教授領導的研究團隊，涵蓋組織病理學、分子病理與人工智能等方向，科研架構係統完善、交叉融合。2020年，Ströbel教授與西門子聯合發起“Cancer Scout”人工智能研究項目，獲得德國聯邦教育與研究部（BMBF）資助，總金額高達960萬歐元。該項目致力於開發一種基於AI的“數字活檢”gongju，liyongyishengzairichangzhenduanzhongzuichangyongdechangguibingliqiepiantuxiang，yucehuanzhezhongliushifoucunzaiguanjiandefenzitubian，congerzaiwuxuewaifenzijiancedeqingkuangxia，fuzhupanduanbingrenshifoushihebaxiangzhiliao。xiangmugoujianleyigedaxing、跨中心的圖像-分子數據庫，收集成千上萬例肺癌、結jie直zhi腸chang癌ai等deng實shi體ti瘤liu的de樣yang本ben，通tong過guo深shen度du學xue習xi模mo型xing識shi別bie圖tu像xiang中zhong極ji其qi細xi微wei的de細xi胞bao形xing態tai與yu分fen子zi突tu變bian之zhi間jian的de潛qian在zai關guan聯lian。這zhe項xiang技ji術shu有you望wang在zai降jiang低di診zhen斷duan成cheng本ben、提升診斷效率的同時，為德國每年近50萬例新發癌症患者提供更便捷、普及的精準醫療方案。Ströbel教授表示，自己早在1993年(nian)就(jiu)曾(zeng)訪(fang)問(wen)中(zhong)國(guo)武(wu)漢(han)，對(dui)中(zhong)國(guo)醫(yi)療(liao)體(ti)係(xi)的(de)發(fa)展(zhan)始(shi)終(zhong)保(bao)持(chi)高(gao)度(du)興(xing)趣(qu)。他(ta)即(ji)將(jiang)與(yu)深(shen)圳(zhen)知(zhi)名(ming)大(da)學(xue)附(fu)屬(shu)醫(yi)院(yuan)開(kai)啟(qi)深(shen)度(du)合(he)作(zuo)，同(tong)時(shi)也(ye)非(fei)常(chang)期(qi)待(dai)與(yu)仁(ren)醫(yi)醫(yi)療(liao)團(tuan)隊(dui)的(de)後(hou)續(xu)合(he)作(zuo)，認(ren)為(wei)這(zhe)將(jiang)為(wei)他(ta)帶(dai)來(lai)一(yi)次(ci)全(quan)新(xin)的(de)對(dui)中(zhong)國(guo)的(de)理(li)解(jie)與(yu)體(ti)驗(yan)。
At 9:30 am on June 10, the team of three from Gloryren went to the University Medical Center Göttingen and visited Prof. Ströbel, the Director of the Institute of Pathology, Deputy Spokesperson of the Göttingen Comprehensive Cancer Center (G-CCC), and President of the German Division of the International Academy of Pathology(IAP). They engaged in in-depth discussions regarding Sino-German cooperation in the field of precision pathological diagnosis. Prof. Ströbel is a prominent figure in the field of pathology in Germany. He has co-authored numerous chapters of 2004, 2015, and 2021 editions of the World Health Organization (WHO) Classification of Tumors Volume on “Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart”. As the President of the Annual Meeting of the German Society of Pathology in 2025, he will preside over this annual academic event in Leipzig from June 12 to 14. Founded in 1737, the University of Göttingen is one of Germany's oldest and most academically renowned institutions. Its affiliated medical center serves as the only certified highest-level healthcare provider in southern Lower Saxony, playing a central role in Germany's medical system. The Institute of Pathology handles approximately 45,000 cases annually, preparing and evaluating around 200,000 histological samples, with fully digitized diagnostic workflows. In research, it has five professor-led teams focusing on histopathology, molecular pathology, and artificial intelligence, featuring an integrated and interdisciplinary research framework. In 2020, Prof. Ströbel co-initiated the "Cancer Scout" AI-related research project with Siemens, receiving a grant of €9.6 million from the German Federal Ministry of Education and Research (BMBF). This project aims to develop an AI-based "digital biopsy" tool that analyzes the histological images—the most common diagnostic resource—to predict key molecular changes in tumors, thereby guiding targeted therapy decisions without additional molecular testing. The project has established a large-scale, multi-center image-molecular database, which contains thousands of samples from solid tumor cases, including lung cancer and colorectal cancer. Through deep learning algorithms, it identifies subtle correlations between cellular morphology and molecular alterations. This technology promises to reduce diagnostic costs, improve efficiency, and provide more accessible precision medicine for nearly 500,000 new cancer patients in Germany each year. Prof. Ströbel shared that he first visited Wuhan, China as early as 1993 and has since maintained a keen interest in the development of China’s healthcare system. He is set to launch a comprehensive collaboration with a prominent university-affiliated hospital in Shenzhen and has showed great interest in the future cooperation with the team of Gloryren, which will offer fresh perspectives to see China.
